We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 10.50 | 0.58% | 1,810.00 | 1,807.50 | 1,808.50 | 1,809.00 | 1,792.00 | 1,797.00 | 4,235,825 | 16:35:18 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 15.10 | 74.42B |
From May 2022 to May 2024
0458 GMT - Wuxi Biologics (Cayman) Inc. is one of the most mentioned companies in the news over the past six hours, according to Factiva data, after it agreed to license T-cell-engaging antibodies to GSK PLC. Wuxi Biologics said Thursday that the deal was for exclusive licenses for up to four TCE antibodies. GSK will make a $40 million up-front payment to Wuxi and up to $1.46 billion in additional payments for R&D and other milestones along with tiered royalties on net sales, Wuxi Biologics said. The Chinese company's Hong Kong shares rose by as much as 7.7% in early trade before the gains eased to 2.5% ahead of the midday trading break. Dow Jones & Co. owns Factiva. (jacques.vanwersch@dowjones.com)
(END) Dow Jones Newswires
January 05, 2023 00:13 ET (05:13 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
